The final allocation results for the initial public offering of JIANGXI BIO (06915) have been announced.

The company issued a total of 36.2345 million shares globally, with the Hong Kong public offering portion accounting for 10% and the international offering making up the remaining 90%.

The final offer price has been set at HK$11.2 per share.

Net proceeds from the global offering are expected to be approximately HK$338.8 million.

Each board lot consists of 500 shares.

The company's H-shares are scheduled to commence trading on the Stock Exchange at 9:00 a.m. on Tuesday, June 30, 2026 (Hong Kong time).

The Hong Kong public offering was significantly oversubscribed by approximately 476.56 times.

The international offering portion was oversubscribed by about 4.25 times.